OPEN ACCESS

IOASD Journal of Medical and Pharmaceutical Sciences

IOASD J Med Pharm Sci, Vol-3, Iss-3, Jul-Sept., 2026
Frequency: Quarterly
ISSN: 3049-0294 (Online)
ISSN: 3049-3773 (Print)
Homepage: https://ioasdpublisher.com/ioasdjmps



The Neurobiological Architecture of Stress: Categorization, Mechanisms, and Mitigation

Mrs. N. Swathisree[1*]
[1]Assistant Professor, Department of Biochemistry, St. Pious X Degree and PG College for Women

Corresponding Author: Mrs. N. Swathisree
DOI: 10.67224/ioasdjmps.2026.v03i03.020
Assistant Professor, Department of Biochemistry, St. Pious X Degree and PG College for Women | Email: swathisree.1213@stpiouscollege.org

ABSTRACT

Stress is a multifaceted physiological and psychological response to perceived threats or challenges, characterized by a complex interplay of neuroendocrine, neurochemical, and behavioral adaptations. This academic paper synthesizes contemporary research to delineate the neurobiological architecture of stress across its primary categories: acute, episodic, and chronic. A significant focus is placed on the "chemical highway" disruption, where the delicate balance of serotonin, dopamine, GABA, and glutamate is compromised, leading to profound effects on mood, cognition, and physical health. Acute stress triggers immediate physiological mobilization through the hypothalamic-pituitary-adrenal (HPA) axis, while chronic stress leads to maladaptive changes such as neuroinflammation, synaptic remodeling, and hippocampal atrophy. Episodic stress, representing recurring acute events, bridges these states, often leading to cumulative allostatic load and fluctuating neurobiological markers. The report further details the physical and mental signs associated with these stress types, ranging from tachycardia and hypercortisolism to anhedonia and memory impairment. Finally, evidence-based mitigation strategies are evaluated, encompassing pharmacological interventions—such as selective serotonin reuptake inhibitors (SSRIs), novel neuroactive steroids, and rapid-acting antidepressants like ketamine—and lifestyle modifications, including physical exercise and dietary supplementation with phytochemicals like crocin, ashwagandha, and anthocyanins. By integrating these findings, this paper provides a comprehensive framework for understanding and addressing the neurobiological impact of stress.

Keywords: hypothalamic-pituitary-adrenal (HPA) axis, hippocampal, neurobiological, pharmacological interventions, Neurotransmitters.

Review Article

Article History
Received: 05-06-2026
Accepted: 01-08-2026
Published: 04-09-2026

INTRODUCTION

Stress is an inherent component of the biological experience, functioning as an evolutionary mechanism for survival. In its optimal form, the stress response enables an organism to adapt to environmental changes and survive acute threats. However, when the frequency, intensity, or duration of stressors exceeds the organism's adaptive capacity, it results in physiological and psychological dysfunction. The neurobiology of stress involves a highly coordinated network involving the central nervous system (CNS), the endocrine system, and the immune system.

Recent advances in transcriptomics and neuroimaging have revealed that stress does not merely "exhaust" the brain but actively reshapes it. From the rapid firing of catecholamines during acute challenges to the epigenetic modifications following early life adversity, stress leaves a lasting molecular signature on the neural architecture. This paper explores these mechanisms, focusing on how stress disrupts the fundamental chemical signaling of the brain and identifying pathways for therapeutic recovery. The study of stress neurobiology has transitioned from simple hormonal models to complex systems-based approaches integrating neuroimmunology and synaptic plasticity.

Neurobiological Categorization of Stress

Acute Stress: The Immediate Response

Acute stress is defined as a short-term reaction to a sudden event. It is characterized by the rapid activation of the sympathetic nervous system and the HPA axis. Physiologically, this leads to an increase in heart rate, blood pressure, and the mobilization of

glucose to support the "fight-or-flight" response. In the brain, acute stress induces a surge in epinephrine and cortisol, which enhances focus and memory encoding for the stressful event, although it may impair the retrieval of unrelated information.

Molecularly, acute stress in mouse models has been shown to increase inhibitory control in the amygdala by activating the transcription of gamma-aminobutyric acid (GABA) receptors. This surge in inhibition may serve as a protective mechanism to prevent over-excitation during the initial stressor. Specifically, acute stress induces active transcription of 6 GABA receptors and only 1 glutamate receptor, indicating an imminent increase in inhibitory control. However, even short-term stressful events can diminish the activity of the mesolimbic dopaminergic reward pathway, leading to a temporary state of reduced responsiveness to reward.

Episodic Stress: The Intermittent Burden

Episodic stress occurs when acute stress events are frequent and repeated, though not continuous. This pattern is often seen in high-pressure occupations, such as tactical military or medical roles, where individuals face recurring crises. Episodic stress is particularly insidious because the body does not have sufficient time to return to its basal state before the next stressor arrives.

Research comparing continuous and intermittent social defeat stress suggests that episodic patterns can lead to divergent behavioral outcomes. While continuous stress might lead to a stable state of social avoidance, intermittent stress can cause fluctuating emotional behaviors and varying levels of brain-derived neurotrophic factor (BDNF) protein in the hippocampus. This category of stress is often associated with the development of "episodic acute stress," where individuals exhibit persistent hyperarousal and anxiety, even between stressful episodes. Intermittent stress can prevent the stabilization of neurochemical levels, keeping the brain in a state of high allostatic load.

Chronic Stress: The Persistent Challenge

Chronic stress arises from long-term exposure to stressful stimuli, such as prolonged social defeat, restraint, or childhood adversity. Unlike acute stress, chronic stress leads to a breakdown of adaptive mechanisms. A hallmark of chronic stress is HPA-axis dysregulation, which may manifest as persistent hypercortisolism or, in later stages, paradoxical hypocortisolism (hyporeactivity).

At the cellular level, chronic stress induces significant morphological changes, including dendritic atrophy in the hippocampus and prefrontal cortex, alongside hypertrophy in the amygdala. These changes are accompanied by low-grade neuroinflammation, characterized by elevated pro-inflammatory cytokines such as TNF-α and IL-6, Chronic stress also leads to the loss of GABAergic interneurons, particularly those expressing parvalbumin (PV) and somatostatin (SST), which results in a release of inhibitory control and subsequent neuronal hyperactivity. Chronic restraint stress (CRS) gradually reduces markers for GABAergic inhibitory interneurons, such as somatostatin (SST), parvalbumin (PV), and glutamic acid decarboxylase-67 (GAD67), in the prefrontal cortex.

Physical and Mental Manifestations of Stress

Physical Signs and Biomarkers

The physical signs of stress are diverse, reflecting the systemic nature of the response. Common physiological markers include:

Cardiovascular Alterations: Increased heart rate, hypertension, and tachycardia are hallmark signs of acute arousal. Chronic stress is further linked to cardiac ischaemic injury and increased cardiovascular tone.

Hormonal Dynamics: Significant increases in serum corticosterone (in rodents) or cortisol (in humans) are standard markers of stress intensity. Chronic social defeat stress can cause HPA-axis dysregulation and imbalances in GABA and glutamate.

Metabolic and Somatic Changes: Adrenal hypertrophy and body weight loss are frequently observed in chronic stress models. Stress can impact skin immune cells, which express receptors for adrenaline, noradrenaline, and dopamine.

Sleep and Feeding: Stress is associated with inhibited sleep, altered feeding patterns (preference for palatable food), and reduced reproductive activity.

Mental and Cognitive Deficits

The psychological impact of stress is equally profound, often manifesting as:

Emotional Dysregulation: This includes hyperarousal, hypervigilance, anxiety-like behaviors, and depressive states.

Anhedonia: A lack of responsiveness to reward is a primary indicator of chronic stress-induced depression. This is linked to reduced striatal dopamine functioning and decreased mesocorticolimbic network functional connectivity.

Cognitive Impairment: Stress severely affects memory systems, including encoding, consolidation, and retrieval. Cognitive decline, reduced neuroplasticity, and impaired spatial memory are common outcomes.

Social Aversion: Increased aversion and reduced reward sensitivity are noted in social stress models.

Disruption of the Chemical Highway

Serotonin: Mood and Regulation:

Serotonin (5-HT) is a key regulator of mood and impulsivity. Chronic stress typically leads to serotonin hypofunction. In models of chronic social defeat, researchers observed increased serotonin turnover but decreased release and uptake in the prefrontal cortex [20]. This is often driven by the downregulation of the serotonin transporter (SERT) and increased DNA methylation of the *Slc6a4* gene.

Chronic social stress also impacts the central serotonergic system by increasing 5-HT1A receptor binding in the dorsal raphe nucleus while decreasing 5-HT2A receptor binding in the amygdala and ventral tegmental area. Low hippocampal 5-HT levels are linked to depressive-like behavior and neuroinflammation.

Dopamine: Reward and Motivation

Dopamine (DA) is essential for reward processing. Stress-induced disruption of the mesolimbic dopaminergic pathway is a primary driver of anhedonia. Chronic stress leads to reduced striatal dopamine functioning and decreased functional connectivity within the mesocorticolimbic network.

In the nucleus accumbens, chronic stress can cause dopamine hyperfunction when combined with palatable food intake. Generally, however, stress leads to reduced dopamine levels, decreased D2 receptor expression, and D3 receptor overexpression, correlating with negative mood and hyperarousal. Dopamine D1 receptors in the dentate gyrus are crucial for the antidepressant actions of SSRIs.

GABA and Glutamate: The Excitation-Inhibition Imbalance

GABAergic System: While acute stress initially increases inhibitory control, chronic stress leads to the depletion of GABAergic interneurons (PV and SST) in the prefrontal cortex and amygdala. This reduction in GABAergic tone results in disinhibition and amygdala hyperactivity.Chronic stress also regulates tonic inhibition in Thy1-expressing neurons in the amygdala.

Glutamate System: Chronic stress is associated with increased glutamatergic activity. In the medial preoptic area, elevated glutamatergic activity suppresses midbrain dopaminergic and serotonergic activity, driving depression-like states. Chronic stress also disturbs the glutamine-glutamate-GABA cycle in the striatum and hippocampus.

Pharmacological Interventions

SSRI/SNRI: Agents like Fluoxetine and Sertraline increase synaptic serotonin and stimulate

GABA Modulators: Benzodiazepines and novel GABAA receptor agonists target the inhibitory deficit. Dendrite-targeting GABAA receptor agonists show efficacy independent of sex.

Neuroactive Steroids: These modulate the GABA pathway and show promise for MDD and postpartum depression.

Rapid-Acting Agents: Ketamine restores synaptic plasticity and reduces hyperarousal.

Adrenergic Blockers: Prazosin and propranolol manage adrenergic symptoms in PTSD.

Lifestyle and Dietary Approaches

Physical Exercise: Exercise reduces clinical symptoms, restores neuroplasticity, and improves hippocampal memory by increasing BDNF.

Nutraceuticals: Phytochemicals like Crocin (from saffron), Ashwagandha, and Theanine boost neurotransmitters and modulate the HPA axis. Anthocyanins from purple sweet potato improve neurotransmitter levels and locomotor activity.

Supplements: CBD, 5-HTP, and specific anxiolytic nutraceuticals (Chamomile, Valerian root, Rhodiola Rosea) can boost neurotransmitter levels.

Synaptic Impact: A Visual Analysis

The neurobiological changes discussed—specifically the imbalance between excitation and inhibition—are manifested at the synaptic level.



Figure 1: Illustration of synaptic disruption caused by stress. The graphic depicts the compromise of neurotransmitter release (serotonin, dopamine, GABA, and glutamate) and the subsequent impact on postsynaptic receptors, leading to the "chemical highway" imbalance.

As shown in the illustration, the physical architecture of the synapse undergoes significant changes under stress. The reduction in GABAergic inhibitory markers and the surge in glutamatergic activity create a state of neural volatility. This visual evidence supports the molecular findings of reduced synaptic markers such as VGLUT1 and the gradual loss of interneuron integrity observed in longitudinal studies.

CONCLUSION

The neurobiological architecture of stress is a complex system of adaptive and maladaptive responses. While acute stress utilizes inhibitory GABAergic pathways to maintain homeostasis, chronic stress leads to a catastrophic failure of these systems, characterized by the depletion of serotonin and dopamine, the loss of GABAergic inhibition, and a state of glutamatergic hyperactivity. Through a combination of targeted pharmacological interventions and lifestyle modifications, it is possible to mitigate these effects and enhance resilience. Future research must focus on the sex-specific microcircuits and epigenetic modifications that underpin these pathways.

REFERENCES

- Arnsten, A. F. T. (2009). Stress signalling pathways that impair prefrontal cortex structure and function. *Nature Reviews Neuroscience, 10*(6), 410–422.
- McEwen, B. S. (2007). Physiology and neurobiology of stress and adaptation: Central role of the brain. *Physiological Reviews, 87*(3), 873–904.
- McEwen, B. S., & Akil, H. (2020). Revisiting the stress concept: Implications for affective disorders. *Journal of Neuroscience, 40*(1), 12–21.
- Joëls, M., Pu, Z., Wiegert, O., Oitzl, M. S., & Krugers, H. J. (2006). Learning under stress: How does it work? *Trends in Cognitive Sciences, 10*(4), 152–158.
- Lupien, S. J., McEwen, B. S., Gunnar, M. R., & Heim, C. (2009). Effects of stress throughout the lifespan on the brain, behaviour and cognition. *Nature Reviews Neuroscience, 10*(6), 434–445.
- Alqadeeri, F. K., Yahya, R. A., Azab, A. E., Alzwaqi, A. A., Shahit, A. A., & Alrqei, M. M. (2025). Recent Advancement Laparoscope Tools and Technique. *IOASD Journal of Medical and Pharmaceutical Sciences*, *2*(2), 60-63.
- Ekpo, S. E., Ekeng, E. B., Effiom, A. B., Aniedi-Abasi, M. I., Inyang, F. B., Eso, I. J., ... & Asanyi, E. J. (2025). Counselling Collaboration, Critical Care Pharmacy and the Need for Outpatient Treatment and Management in Cross River State, Nigeria. *IOASD Journal of Medical and Pharmaceutical Sciences*, *2*(3), 134-136.
- Krystal, J. H., Abdallah, C. G., Sanacora, G., Charney, D. S., & Duman, R. S. (2019). Ketamine: A paradigm shift for depression research and treatment. *Neuron, 101*(5), 774–778.
- Sanacora, G., Treccani, G., & Popoli, M. (2012). Towards a glutamate hypothesis of depression. *Nature Reviews Neuroscience, 13*(9), 609–620.
- Popoli, M., Yan, Z., McEwen, B. S., & Sanacora, G. (2012). The stressed synapse: The impact of stress and glucocorticoids on glutamate transmission. *Nature Reviews Neuroscience, 13*(1), 22–37.
- Nestler, E. J., & Carlezon, W. A. (2006). The mesolimbic dopamine reward circuit in depression. *Biological Psychiatry, 59*(12), 1151–1159.
- Krishnan, V., & Nestler, E. J. (2008). The molecular neurobiology of depression. *Nature, 455*(7215), 894–902.
- Ressler, K. J., & Nemeroff, C. B. (2000). Role of serotonergic and noradrenergic systems in depression and anxiety disorders. *Depression and Anxiety, 12*(Suppl. 1), 2–19.
- Sapolsky, R. M. (2000). Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. *Archives of General Psychiatry, 57*(10), 925–935.
- Gold, P. W. (2015). The organization of the stress system and its dysregulation in depressive illness. *Molecular Psychiatry, 20*(1), 32–47.
- Erickson, K. I., Gildengers, A. G., & Butters, M. A. (2013). Physical activity and brain plasticity in late adulthood. *Dialogues in Clinical Neuroscience, 15*(1), 99–108.
- Cotman, C. W., & Berchtold, N. C. (2002). Exercise: A behavioural intervention to enhance brain health and plasticity. *Trends in Neurosciences, 25*(6), 295–301.
- Lopresti, A. L., Smith, S. J., Malvi, H., & Kodgule, R. (2019). An investigation into the stress-relieving and pharmacological actions of *Withania somnifera* (Ashwagandha). *Medicine, 98*(37), e17186.
- Pitsikas, N. (2015). Crocus sativus L. and its constituents as potential cognitive enhancers. *Journal of Traditional and Complementary Medicine, 5*(1), 1–6.
- WHO. (2023). *Mental health*. World Health Organization.